Investigating the effect of dexmedetomidine in restless in orthopedic patients candidates for general anesthesia in recovery

Investigating the effect of dexmedetomidine in agitation in elective upper limb orthopedic patients candidates for general anesthesia in recovery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230819059181N1

Enrollment

150

Registered

2023-09-10

Start date

2023-12-22

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Agitation. Restlessness and agitation

Interventions

Intervention 1: Intervention group: Will receive dexmedetomidine (Exir Company) with a dose of 0.4 µg per kilogram from induction of anesthesia to extubation. Intervention 2: Control group: A placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Orthopedic patients candidates for general anesthesia in elective upper surgery

Exclusion criteria

Exclusion criteria: Urgent patients Patients with uncontrolled disease

Design outcomes

Primary

Measure	Time frame
Agitation. Timepoint: 15 and 30 minutes after entering recovery. Method of measurement: Ricker sedation-agitation scale.	—

Secondary

Measure	Time frame
Pain. Timepoint: 15 and 30 minutes after entering recovery. Method of measurement: Visual Analog Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Abitorabi

Ardabil University of Medical Sciences

atlantis.321@yahoo.com009845133720209

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026